AbbVie has secured UK marketing authorisation for ELAHERE (mirvetuximab soravtansine), the first antibody-drug conjugate (ADC ...

Using microneedle arrays developed at Carnegie Melon, microdosed with a known chemotherapeutic agent delivered directly to ...

Researchers at the University of Florida have developed a new mRNA-based vaccine that, when combined with checkpoint ...

However, yesterday GSK announced that the FDA has extended the review period for Blenrep to give the agency time to review ...

This month’s executive moves span a diverse range of organisations – from CDMOs and genomics platforms to diagnostics and ...

Back in May, health data company Datavant announced its plans to acquire Aetion, creating a formidable player in the ...

Pharma’s next big leap won’t come from the lab. It’ll come from outside the lab, where the rules of narrative, attention, and ...

According to the company, H1 net sales growth was driven by continued global demand for key medicines, including JARDIANCE, a ...

On day three of BIO 2025, editor-in-chief Jonah Comstock caught up with OS Therapies CEO Paul Romness and EVERSANA VP of ...

Alexion, the rare disease unit acquired by AstraZeneca nearly five years ago, has announced high-level positive results from ...

The FDA appears to have won its staring contest with Sarepta over shipments of Elevidys, after the company blinked and agreed ...

SCOPE is testing administration of intramuscular SCIB1 and intradermal iSCIB1+, which codes for various melanoma antigens ...